NSC23766, a specific inhibitor of Rac1, has recently been shown to protect against cerebral ischemic injury, although the effects of
NSC23766 in a diabetic model have not been examined. Therefore, the aim of our study was to investigate if
NSC23766 provided neuroprotection in
streptozotocin-induced diabetic rats and to determine the potential mechanism through which
NSC23766 works. Diabetic Sprague-Dawley rats were subjected to right
middle cerebral artery occlusion (MCAO) for 90 min.
NSC23766 (10 or 30 mg kg(-1)) or isotonic saline were administered intraperitoneally twice daily starting 24 h after
cerebral ischemia, for three consecutive days.
Cerebral infarct volume, neurological deficit scores, neuronal apoptosis, and the release of
cytochrome c, as well as the generation of ROS and mitochondrial integrity, were evaluated 96 h after reperfusion. In addition, the mitochondrial translocation of p53 and the expression of p53-upregulated modulator of apoptosis (PUMA) in the mitochondria of the cerebral ischemic cortex were determined by western blotting.
NSC23766 not only ameliorated post-ischemic neuronal apoptosis but also decreased
cerebral ischemia-induced mitochondrial p53 translocation and the expression of PUMA in mitochondria in diabetic rats. Thus, our data indicate that
NSC23766 has therapeutic potential against cerebral ischemic
reperfusion injury and that
NSC23766 significantly ameliorates neuronal apoptosis by suppressing mitochondrial p53 translocation in
streptozotocin-induced diabetic rats.